Overview of Dr. Mellinghoff
Dr. Ingo Mellinghoff is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center. He received his medical degree from Technical University Munich Faculty of Medicine and has been in practice 24 years. He is one of 503 doctors at Memorial Sloan Kettering Cancer Center and one of 503 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2004- UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 1998 - 1999
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1995 - 1998
Technical University Munich Faculty of MedicineClass of 1993
Certifications & Licensure
NH State Medical License 2024 - 2026
CA State Medical License 1997 - 2025
NY State Medical License 2008 - 2025
Awards, Honors, & Recognition
- Member (elected) Association of American Physicians, 2020
- Member (elected) American Society of Clinical Investigation, 2013
Clinical Trials
- EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas Start of enrollment: 2011 Jan 07
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.Craig Horbinski, David A Solomon, Rimas V Lukas, Roger J Packer, Priscilla Brastianos
JAMA Oncology. 2024-12-26 - Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal
Clinical Cancer Research. 2024-10-15 - 7 citationsThe biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of I...Martin J van den Bent, Pim J French, Daniel Brat, Joerg C Tonn, Mehdi Touat
Neuro-Oncology. 2024-10-03
Abstracts/Posters
- Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)Ingo K Mellinghoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
IDH Inhibitor Activity in Brain Cancer Persists with Longer Follow-UpNovember 24th, 2024- Health Canada Approves First and Only Oral Treatment for Brain CancerOctober 22nd, 2024
- IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
- Join now to see all
Professional Memberships
- Member
- American Association for Cancer Research - AACRMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
